The programmed death-1 immune-suppressive pathway: Barrier to antitumor immunity

Journal of Immunology

Volumn 193, Issue 8, 2014, Pages 3835-3841

  Ostrand Rosenberg, Suzanne ^a   Horn, Lucas A ^a   Haile, Samuel T ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PD 1; MONOCLONAL ANTIBODY PD L1; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; UNCLASSIFIED DRUG; B7 ANTIGEN; FAS LIGAND; PROGRAMMED DEATH 1 RECEPTOR;

AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER PROGNOSIS; CELLULAR IMMUNITY; DRUG EFFICACY; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TREATMENT RESPONSE; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; APOPTOSIS; CD8+ T LYMPHOCYTE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; NEOPLASM; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, CD274; ANTIGENS, CD80; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; FAS LIGAND PROTEIN; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84907486438     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401572     Document Type: Review

References (79)

1. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
2. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
3. Wolchok, J. D., H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, et al. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369: 122-133.
4. Topalian, S. L., M. Sznol, D. F. McDermott, H. M. Kluger, R. D. Carvajal, W. H. Sharfman, J. R. Brahmer, D. P. Lawrence, M. B. Atkins, J. D. Powderly, et al. 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32: 1020-1030.
5. Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11: 3887-3895.
6. Shinohara, T., M. Taniwaki, Y. Ishida, M. Kawaichi, and T. Honjo. 1994. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 23: 704-706.
7. Freeman, G. J. 2008. Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc. Natl. Acad. Sci. USA 105: 10275-10276.
8. Nishimura, H., M. Nose, H. Hiai, N. Minato, and T. Honjo. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151.
9. Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5: 1365-1369.
10. Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192: 1027-1034.
11. Iwai, Y., M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99: 12293-12297.
12. Brown, J. A., D. M. Dorfman, F. R. Ma, E. L. Sullivan, O. Munoz, C. R. Wood, E. A. Greenfield, and G. J. Freeman. 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170: 1257-1266.
13. Curiel, T. J., S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K. L. Knutson, B. Daniel, M. C. Zimmermann, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9: 562-567.
14. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
15. Keir, M. E., M. J. Butte, G. J. Freeman, and A. H. Sharpe. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704.
16. Blank, C., I. Brown, A. C. Peterson, M. Spiotto, Y. Iwai, T. Honjo, and T. F. Gajewski. 2004. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64: 1140-1145.
17. Petrovas, C., J. P. Casazza, J. M. Brenchley, D. A. Price, E. Gostick, W. C. Adams, M. L. Precopio, T. Schacker, M. Roederer, D. C. Douek, and R. A. Koup. 2006. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 203: 2281-2292.
18. Taube, J. M., R. A. Anders, G. D. Young, H. Xu, R. Sharma, T. L. McMiller, S. Chen, A. P. Klein, D. M. Pardoll, S. L. Topalian, and L. Chen. 2012. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4: 127ra137.
19. Saudemont, A., N. Jouy, D. Hetuin, and B. Quesnel. 2005. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 105: 2428-2435.
20. Sznol, M., and L. Chen. 2013. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin. Cancer Res. 19: 1021-1034.
21. Kondo, A., T. Yamashita, H. Tamura, W. Zhao, T. Tsuji, M. Shimizu, E. Shinya, H. Takahashi, K. Tamada, L. Chen, et al. 2010. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood 116: 1124-1131.
22. Parsa, A. T., J. S. Waldron, A. Panner, C. A. Crane, I. F. Parney, J. J. Barry, K. E. Cachola, J. C. Murray, T. Tihan, M. C. Jensen, et al. 2007. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13: 84-88.
23. Crane, C. A., A. Panner, J. C. Murray, S. P. Wilson, H. Xu, L. Chen, J. P. Simko, F. M. Waldman, R. O. Pieper, and A. T. Parsa. 2009. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene 28: 306-312.
24. Marzec, M., Q. Zhang, A. Goradia, P. N. Raghunath, X. Liu, M. Paessler, H. Y. Wang, M. Wysocka, M. Cheng, B. A. Ruggeri, and M. A. Wasik. 2008. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl. Acad. Sci. USA 105: 20852-20857.
25. Gong, A. Y., R. Zhou, G. Hu, X. Li, P. L. Splinter, S. P. O'Hara, N. F. LaRusso, G. A. Soukup, H. Dong, and X. M. Chen. 2009. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J. Immunol. 182: 1325-1333.
26. Wang, J., L. Cheng, Z. Wondimu, M. Swain, P. Santamaria, and Y. Yang. 2009. Cutting edge: CD28 engagement releases antigen-activated invariant NKT cells from the inhibitory effects of PD-1. J. Immunol. 182: 6644-6647.
27. Okazaki, T., A. Maeda, H. Nishimura, T. Kurosaki, and T. Honjo. 2001. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. USA 98: 13866-13871.
28. Yao, S., S. Wang, Y. Zhu, L. Luo, G. Zhu, S. Flies, H. Xu, W. Ruff, M. Broadwater, I. H. Choi, et al. 2009. PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 113: 5811-5818.
29. Selenko-Gebauer, N., O. Majdic, A. Szekeres, G. Höfler, E. Guthann, U. Korthäuer, G. Zlabinger, P. Steinberger, W. F. Pickl, H. Stockinger, et al. 2003. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J. Immunol. 170: 3637-3644.
30. Tsushima, F., S. Yao, T. Shin, A. Flies, S. Flies, H. Xu, K. Tamada, D. M. Pardoll, and L. Chen. 2007. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 110: 180-185.
31. Sakuishi, K., L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207: 2187-2194.
32. Sheppard, K.A., L. J. Fitz, J. M. Lee, C. Benander, J. A. George, J. Wooters, Y. Qiu, J. M. Jussif, L. L. Carter, C. R. Wood, and D. Chaudhary. 2004. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 574: 37-41.
33. Patsoukis, N., D. Sari, and V. A. Boussiotis. 2012. PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle 11: 4305-4309.
34. Parry, R. V., J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, and J. L. Riley. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25: 9543-9553.
35. Charlton, J. J., I. Chatzidakis, D. Tsoukatou, D. T. Boumpas, G. A. Garinis, and C. Mamalaki. 2013. Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner. J. Immunol. 190: 6104-6114.
36. Gibbons, R. M., X. Liu, V. Pulko, S. M. Harrington, C. J. Krco, E. D. Kwon, and H. Dong. 2012. B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. OncoImmunology 1: 1061-1073.
37. Shamim, M., S. G. Nanjappa, A. Singh, E. H. Plisch, S. E. LeBlanc, J. Walent, J. Svaren, C. Seroogy, and M. Suresh. 2007. Cbl-b regulates antigen-induced TCR down-regulation and IFN-gamma production by effector CD8 T cells without affecting functional avidity. J. Immunol. 179: 7233-7243.
38. Karwacz, K., C. Bricogne, D. MacDonald, F. Arce, C. L. Bennett, M. Collins, and D. Escors. 2011. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol. Med. 3: 581-592.
39. Fife, B. T., K. E. Pauken, T. N. Eagar, T. Obu, J. Wu, Q. Tang, M. Azuma, M. F. Krummel, and J. A. Bluestone. 2009. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 10: 1185-1192.
40. Yokosuka, T., M. Takamatsu, W. Kobayashi-Imanishi, A. Hashimoto-Tane, M. Azuma, and T. Saito. 2012. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209: 1201-1217.
41. Azuma, T., S. Yao, G. Zhu, A. S. Flies, S. J. Flies, and L. Chen. 2008. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111: 3635-3643.
42. Park, J. J., R. Omiya, Y. Matsumura, Y. Sakoda, A. Kuramasu, M. M. Augustine, S. Yao, F. Tsushima, H. Narazaki, S. Anand, et al. 2010. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116: 1291-1298.
43. Paterson, A. M., K. E. Brown, M. E. Keir, V. K. Vanguri, L. V. Riella, A. Chandraker, M. H. Sayegh, B. R. Blazar, G. J. Freeman, and A. H. Sharpe. 2011. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J. Immunol. 187: 1097-1105.
44. Francisco, L. M., V. H. Salinas, K. E. Brown, V. K. Vanguri, G. J. Freeman, V. K. Kuchroo, and A. H. Sharpe. 2009. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206: 3015-3029.
45. Amarnath, S., C. W. Mangus, J. C. Wang, F. Wei, A. He, V. Kapoor, J. E. Foley, P. R. Massey, T. C. Felizardo, J. L. Riley, et al. 2011. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci. Transl. Med. 3: 111ra120.
46. Zhou, Q., M. E. Munger, S. L. Highfill, J. Tolar, B. J. Weigel, M. Riddle, A. H. Sharpe, D. A. Vallera, M. Azuma, B. L. Levine, et al. 2010. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 116: 2484-2493.
47. Yi, T., X. Li, S. Yao, L. Wang, Y. Chen, D. Zhao, H. F. Johnston, J. S. Young, H. Liu, I. Todorov, et al. 2011. Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7.1 in allogeneic recipients. J. Immunol. 186: 2739-2749.
48. Gao, Q., X. Y. Wang, S. J. Qiu, I. Yamato, M. Sho, Y. Nakajima, J. Zhou, B. Z. Li, Y. H. Shi, Y. S. Xiao, et al. 2009. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 15: 971-979.
49. Ghebeh, H., S. Mohammed, A. Al-Omair, A. Qattan, C. Lehe, G. Al-Qudaihi, N. Elkum, M. Alshabanah, S. Bin Amer, A. Tulbah, et al. 2006. The B7-H1 (PDL1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8: 190-198.
50. Hamanishi, J., M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, T. Higuchi, H. Yagi, K. Takakura, N. Minato, et al. 2007. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 104: 3360-3365.
51. Konishi, J., K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura. 2004. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 10: 5094-5100.
52. Nakanishi, J., Y. Wada, K. Matsumoto, M. Azuma, K. Kikuchi, and S. Ueda. 2007. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother. 56: 1173-1182.
53. Ohigashi, Y., M. Sho, Y. Yamada, Y. Tsurui, K. Hamada, N. Ikeda, T. Mizuno, R. Yoriki, H. Kashizuka, K. Yane, et al. 2005. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11: 2947-2953.
54. Wu, C., Y. Zhu, J. Jiang, J. Zhao, X. G. Zhang, and N. Xu. 2006. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 108: 19-24.
55. Lipson, E. J., J. G. Vincent, M. Loyo, L. T. Kagohara, B. S. Luber, H. Wang, H. Xu, S. K. Nayar, T. S. Wang, D. Sidransky, et al. 2013. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol. Res. 1: 54-63.
56. Brahmer, J. R., C. G. Drake, I. Wollner, J. D. Powderly, J. Picus, W. H. Sharfman, E. Stankevich, A. Pons, T. M. Salay, T. L. McMiller, et al. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28: 3167-3175.
57. Thompson, R. H., S. M. Kuntz, B. C. Leibovich, H. Dong, C. M. Lohse, W. S. Webster, S. Sengupta, I. Frank, A. S. Parker, H. Zincke, et al. 2006. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with longterm follow-up. Cancer Res. 66: 3381-3385.
58. Inman, B. A., T. J. Sebo, X. Frigola, H. Dong, E. J. Bergstralh, I. Frank, Y. Fradet, L. Lacombe, and E. D. Kwon. 2007. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109: 1499-1505.
59. Frigola, X., B. A. Inman, C. M. Lohse, C. J. Krco, J. C. Cheville, R. H. Thompson, B. Leibovich, M. L. Blute, H. Dong, and E. D. Kwon. 2011. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin. Cancer Res. 17: 1915-1923.
60. Rossille, D., M. Gressier, D. Damotte, D. Maucort-Boulch, C. Pangault, G. Semana, S. Le Gouill, C. Haioun, K. Tarte, T. Lamy, et al.; for the Groupe Ouest-Est des Leucémies et Autres Maladies du Sang. 2014. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 10.1038/leu.2014.137.
61. Iwai, Y., S. Terawaki, and T. Honjo. 2005. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17: 133-144.
62. Strome, S. E., H. Dong, H. Tamura, S. G. Voss, D. B. Flies, K. Tamada, D. Salomao, J. Cheville, F. Hirano, W. Lin, et al. 2003. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63: 6501-6505.
63. Curran, M. A., W. Montalvo, H. Yagita, and J. P. Allison. 2010. PD-1 and CTLA- 4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107: 4275-4280.
64. Duraiswamy, J., K. M. Kaluza, G. J. Freeman, and G. Coukos. 2013. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73: 3591-3603.
65. Highfill, S. L., Y. Cui, A. J. Giles, J. P. Smith, H. Zhang, E. Morse, R. N. Kaplan, and C. L. Mackall. 2014. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6: 237ra67.
66. Hirano, F., K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D. B. Flies, J. S. Lau, G. Zhu, et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65: 1089-1096.
67. Duraiswamy, J., G. J. Freeman, and G. Coukos. 2013. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 73: 6900-6912.
68. Ahmadzadeh, M., L. A. Johnson, B. Heemskerk, J. R. Wunderlich, M. E. Dudley, D. E. White, and S. A. Rosenberg. 2009. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544.
69. Bald, T., J. Landsberg, D. Lopez-Ramos, M. Renn, N. Glodde, P. Jansen, E. Gaffal, J. Steitz, R. Tolba, U. Kalinke, et al. 2014. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 4: 674-687.
70. Nomi, T., M. Sho, T. Akahori, K. Hamada, A. Kubo, H. Kanehiro, S. Nakamura, K. Enomoto, H. Yagita, M. Azuma, and Y. Nakajima. 2007. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13: 2151-2157.
71. Deng, L., H. Liang, B. Burnette, M. Beckett, T. Darga, R. R. Weichselbaum, and Y. X. Fu. 2014. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124: 687-695.
72. Lipson, E. J., W. H. Sharfman, C. G. Drake, I.Wollner, J. M. Taube, R. A. Anders, H. Xu, S. Yao, A. Pons, L. Chen, et al. 2013. Durable cancer regression offtreatment and effective reinduction therapy with an anti-PD-1 antibody. Clin. Cancer Res. 19: 462-468.
73. Hamid, O., C. Robert, A. Daud, F. S. Hodi, W. J. Hwu, R. Kefford, J. D. Wolchok, P. Hersey, R. W. Joseph, J. S. Weber, et al. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369: 134-144.
74. Butte, M. J., M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122.
75. Haile, S. T., J. J. Bosch, N. I. Agu, A. M. Zeender, P. Somasundaram, M. K. Srivastava, S. Britting, J. B. Wolf, B. R. Ksander, and S. Ostrand-Rosenberg. 2011. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J. Immunol. 186: 6822-6829.
76. Haile, S. T., S. P. Dalal, V. Clements, K. Tamada, and S. Ostrand-Rosenberg. 2013. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J. Immunol. 191: 2829-2836.
77. Haile, S. T., L. A. Horn, and S. Ostrand-Rosenberg. 2014. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation. Cancer Immunol. Res. 2: 610-615.
78. Peach, R. J., J. Bajorath, J. Naemura, G. Leytze, J. Greene, A. Aruffo, and P. S. Linsley. 1995. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28. J. Biol. Chem. 270: 21181-21187.
79. Lin, D. Y., Y. Tanaka, M. Iwasaki, A. G. Gittis, H. P. Su, B. Mikami, T. Okazaki, T. Honjo, N. Minato, and D. N. Garboczi. 2008. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl. Acad. Sci. USA 105: 3011-3016.